Literature DB >> 32496393

Fate and Management of Incompletely Excised Solitary Fibrous Tumor of the Orbit: A Case Series and Literature Review.

Chad H Jackson1, Bryan C Hunt2, Gerald J Harris1.   

Abstract

PURPOSE: There is an imperfect correlation between the histology and behavior of solitary fibrous tumor (SFT). In addition, recurrence is common, and dedifferentiation may occur over time. Preferred primary treatment is intact excision, but friable pseudocapsules and tenacious attachments can thwart this goal in the crowded, visually sensitive orbit. This study addresses the fate and appropriate management of incompletely excised orbital SFT.
METHODS: Among a single surgeon's 7-case experience with orbital SFT, 3 cases involved incomplete primary excision, either before (2 cases) or after (1 case) referral. We reviewed the clinicopathologic data in these 3 cases, with follow-up intervals of 18, 21, and 52 years after initial presentation. We reviewed the English-language literature on SFT, with special attention to evolving nomenclature, orbital involvement, recurrence, malignant transformation, and management options.
RESULTS: Benign versus malignant designations of SFT vary with histological and behavioral criteria. Approximately 150 orbital cases have been reported. Published rates of primary malignancy and recurrence across all histologic categories are 6% to 12% and 30% to 37%, respectively. We identified 43 well-documented recurrences (range, 6 months-33 years; median, 3 years) and 10 cases of histological dedifferentiation (range, 14 months-33 years). Because of SFT's rarity and needed follow-up intervals, the value of adjuvant therapy is not yet proven. In follow up of 18, 21, and 52 years after initial presentation, our 3 cases with incomplete excision showed either no recurrence (Case 1) or no morphological dedifferentiation (Cases 2, 3).
CONCLUSION: A treatment algorithm is predicated on the completeness of surgical excision and histological features. However, we recommend case-by-case multidisciplinary decisions in a tumor-board setting.
Copyright © 2020 The American Society of Ophthalmic Plastic and Reconstructive Surgery, Inc.

Entities:  

Mesh:

Year:  2021        PMID: 32496393     DOI: 10.1097/IOP.0000000000001691

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  6 in total

Review 1.  A review of solitary fibrous tumours of the orbit and ocular adnexa.

Authors:  Cornelius René; Paolo Scollo; Dominic O'Donovan
Journal:  Eye (Lond)       Date:  2022-07-13       Impact factor: 4.456

2.  Orbital solitary fibrous tumours: clinicopathological characteristics and recurrence prediction.

Authors:  Xiao-Jin Gao; Xiao-Lin Peng; Yu-Jiao Wang; Wei-Min He
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-08-27       Impact factor: 3.535

3.  Solitary Fibrous Tumors of the Head and Neck: A Single-Institution Study of 52 Patients.

Authors:  Hye Rhyn Chung; Kenric Tam; Albert Y Han; Farres Obeidin; Manando Nakasaki; Dinesh K Chhetri; Maie A St John; Ashley E Kita
Journal:  OTO Open       Date:  2022-07-12

Review 4.  Solitary Fibrous Tumor of the Orbit: A Clinicopathologic Study of Two Cases With Review of the Literature.

Authors:  Mizuho Mitamura; Satoru Kase; Yasuo Suzuki; Takatoshi Sakaguchi; Yuka Suimon; Yoko Dong; Kanako C Hatanaka; Toshiya Sinohara; Manabu Kase; Susumu Ishida
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

5.  Factors for postoperative recurrence of orbital solitary fibrous tumor: an analysis of long-term clinical follow-up results from a Chinese tertiary hospital.

Authors:  Peng Yang; Hao-Cheng Liu; E Qiu; Wei Wang; Jia-Liang Zhang; Li-Bin Jiang; Hong-Gang Liu; Jun Kang
Journal:  BMC Ophthalmol       Date:  2021-01-26       Impact factor: 2.209

6.  Multidisciplinary collaboration for the successful treatment of a giant hepatic solitary fibrous tumor protruding into the thorax: A case report.

Authors:  Jiajun Lin; Shenfeng Huang; Jinfei Wang; Zhifang Cai
Journal:  Exp Ther Med       Date:  2022-05-20       Impact factor: 2.751

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.